NCAM1 and small cell lung carcinoma: In SCLC xenograft models, CD56 targeting resulted in substantial tumor reduction by day 20 post-injection and improved overall survival, suggesting CD56-CAR-T as a viable immunotherapeutic strategy for CD56+ SCLC (63).